Methamphetamine Use Disorder Study

The University of Kansas Medical Center Department of Psychiatry & Behavioral Sciences is conducting a clinical trial of an investigational drug combination to treat moderate to severe methamphetamine use disorder. Study participation can last up to 19 weeks and requires weekly, in-person visits, to the KU Med Center campus for follow-up and testing.

Qualified participants:

• Must use methamphetamine regularly and interested in reducing or stopping use
• Between 18 and 65 years of age
• Can NOT be currently or regularly using opioids
• Not currently enrolled in formal behavioral or pharmacological treatment for substance use disorder

** IMPORTANT: participants cannot be physically dependent on opioids due to the risk of a negative drug reaction**

Qualified participants will receive all study-related medications and procedures at no cost.

Compensation is available for your time.

If you are interested in learning more about this clinical trial, please call 913-588-6440.

Sublocade Long-Term Outcomes

This observational study is looking at the long-term outcomes in individuals adults with Opioid Use Disorder.

Type of Study: Observational

Who can participate: Individuals with a diagnosis of Opioid Use Disorder/Opioid Dependence who have initiated treatment with SUBLOCADE within the past 3 months

How long is participation: Up to 4 years*

Is there compensation? Yes

RECOVER (Bipolar Depression)

The RECOVER Study is a research study that will provide new information about how helpful VNS Therapy (Vagal Nerve Stimulation) is for patients with bipolar depression that has been difficult to treat.

• Type of study: Interventional (Investigational Device)
• Who can participate: Individuals with Bipolar Depression, considered Treatment Resistant (have tried at least four antidepressant treatments and not found helpful), ages 18 or older
• How long is participation: 1-4 years*
• Is there compensation? Yes

KU Autism Research Study

The KU Center on Autism Research and Training (KCART) is recruiting for a study that examines the effects of a medication named Pimavanserin on behavioral rigidity and restrictive repetitive behavior within individuals with Autism Spectrum Disorder, or ASD.

• Type of study: Interventional (Investigational Drug)
• Who can participate: Individuals with a diagnosis of Autism Spectrum Disorder, ages 16-40; must have a caregiver who is willing to help complete study activities
• How long is participation:10 weeks, 6 study visits
• Is there compensation? Yes

FXS Trials (Fragile X Syndrome)

Two studies are recruiting males aged 9 to 45 to participate in potential registration trials for new treatment for FXS, to be followed by a 2-year open-label extension study in which all subjects will receive active treatment

• Type of study: Interventional (Investigational Drug)
• Who can participate: Adolescent males, ages 9-17, weighing ≥ to 55lbs and ≤ to 97th percentile of BMI for age; adult males, ages 18-45, with BMI between 18-36 kg/m2
• How long is participation: 13 weeks
• Is there compensation? Yes